Research suggests that SERMs may help improve bone mineral density in postmenopausal women with osteopenia, a precursor to osteoporosis. For many people, osteoporosis is a silent disease.

It’s estimated more than 10 million Americans over the age of 50 live with this "silent disease." Here's what osteoporosis ...

This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene ...

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and therapeutic role of raloxifene hydrochloride are reviewed. Raloxifene is a selective estrogen-receptor modulator (SERM ...

That's on the horizon. That's a drug that's currently in clinical trials. There are some other so-called SERMs, like Evista, that maybe even better than Evista that are, that are on the horizon ...

There's also a drug called Evista. Evista is a selected estrogen receptor modulator, big word, or SERM. SERMs work uh again to deal with some of the things that happen when you lose estrogen ...

Osteoporosis is a disabling skeletal disorder that is characterized by decreased bone strength, predisposing patients to increased risk of bone fracture. Peak bone mass (maximum bone strength and ...

It’s estimated more than 10 million Americans over the age of 50 live with osteoporosis, a bone disease that causes the bones to become weak and brittle. Osteoporosis, in and of itself ...